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To the Editor: We read with interest the case of
protein-losing enteropathy presented by Chen et al.1
Although the clinical details, laboratory data, and scinti-
graphic findings upheld their impression of protein-losing
enteropathy confined to ascending colon, several
potential pitfalls should be emphasized in the diagnosis
of protein-losing enteropathy by using technetium-
99m-labeled human serum albumin (Tc-99m HSA)
scintigraphy.
Tc-99m HSA scintigraphy is a high-sensitivity diagnostic
tool in imaging protein-losing enteropathy.2 However, any
gastrointestinal bleeding may result in a false-positive
accumulation of enteric Tc-99m HSA activity, because the
radiotracer can leak into the gastrointestinal tract through
blood.3 In addition, in vivo breakdown of the radiotracer
with resultant free pertechnetate concentrating in the gut
may show a false-positive result mimicking radiotracer
exudation. In contrast, the Tc-99m HSA uptake on delayed
images just represents a transit pattern of radiotracer activity
along with bowel lumen rather than the primary site of
protein loss, as non-continuous acquisitions of scintigraphic
images may not grab the intermittent nature of protein loss.4
These phenomena may lead to either incorrect localization
or false-negative results. Therefore, getting acquainted
with these potential pitfalls and detailed assessment of
serial scanning are vital to appropriate diagnosis and
interpretation.
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Technetium-99m-labeled human serum albumin (Tc-99m
HSA) scintigraphy has high sensitivity and specificity in
the diagnosis of protein-losing enteropathy,3 despite some
limitations. False positives may result from active gastro-
intestinal bleeding and in vivo breakdown of Tc-99m HSA,
yielding free pertechnetate from radiolabeling. The former
is easily excluded by fecal occult blood examination and
the latter by the absence of stomach or thyroid visualiza-
tion.4 Tc-99m HSA is stable in vivo, with o0.5% of Tc-
99m HSA found in feces within 24 h.4 Our earlier report5
indicated sufficient labeling efficiency and stability follow-
ing on-site preparation of Tc-99m HSA for clinical
applications. Thus, these two limitations were avoided in
our study. Moreover, there is a very low possibility of a
false positive in our case, because there was no evidence of
radioactivity in the gut of individuals without gastro-
intestinal protein loss.3,6
Another limitation inevitably encountered in the inter-
pretation of Tc-99m HSA images is the identification of
protein loss at the primary site on the delayed image or
at primary or primary-into-secondary multiple sites. Chiu
et al.3 highlighted the importance of serial scanning over
24 h in the imaging of protein-losing enteropathy, because
26% of patients with positive findings had delayed images
24 h after injection, suggesting the intermittent nature of
protein loss from the gut. Two papers7,8 concluded that
multiple sites of protein loss originated in the transit of
bowel activity with its contents from a primary site, rather
than a secondary site, in the absence of the above-
mentioned limitations. Conversely, Wu et al.9 regarded
multiple sites as different primary sites and carried out
treatment. However, none of these papers7–9 confirmed their
examinations by endoscopy or histological examination.
As our study2 did not have the above-mentioned limita-
tions, we concluded that significant radioactivity in one or
more sites of the gastrointestinal tract on the Tc-99m HSA
scan represents leakage of albumin into bowel lumen.6,8
Positive scintigraphic results only provide an indication that
the potential site(s) should be evaluated by pathologic
examination. In our study, we performed series imaging
for up to 24 h and evident radioactivity was obtained only
24 h after injection. We also performed colonoscopy and
pathologic examination, the results of which agreed with the
positive findings on the scans. In conclusion, Tc-99m HSA
scanning is a simple and effective screening method that can
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